Fundraising Fox

Lucence

Founded 2016 · 3 known investors

lucence.com ↗

Lucence develops ultra-sensitive liquid biopsy tests that analyze ctDNA and ctRNA to support earlier detection and personalized treatment decisions for conditions such as cancer and cardiovascular risk. Its products, including LiquidHALLMARK and CardioHemeRISK, are powered by proprietary AmpliMARK and mirror barcoding technologies and are used by physicians and patients for genomic testing.

AI & Machine LearningBiotechDigital Health

Investors · 3

Openspace VenturesBangkok
Heliconia CapitalreportedSingapore
SGInnovatereportedSingapore · $652K – $18M

In the news

Lucence raises $20M to advance liquid biopsybiospectrumasia.com · Nov 2019Cancer Diagnostics Startup, Lucence Raises US $20M In Series A Funding - Thailand Medical Newsthailandmedical.news · Nov 2019S'pore Firm Lucence Raises US$20M To Advance Its Non-Invasive Cancer Detection Techvulcanpost.com · Nov 2019Lucence Raises $20M in Series A Funding - FinSMEsfinsmes.com · Nov 2019Lucence Raises USD $20M Series A Led by IHH Healthcare to Advance Liquid Biopsy for Early Detection of Multiple Cancers - BioSpacebiospace.com · Nov 2019Cancer Diagnostics Firm Lucence Raises $20M | GenomeWebgenomeweb.com · Nov 2019

Frequently asked questions

What does Lucence do?
Lucence develops ultra-sensitive liquid biopsy tests that analyze ctDNA and ctRNA to support earlier detection and personalized treatment decisions for conditions such as cancer and cardiovascular risk. Its products, including LiquidHALLMARK and CardioHemeRISK, are powered by proprietary AmpliMARK and mirror barcoding technologies and are used by physicians and patients for genomic testing.
Who are Lucence's investors?
Lucence's investors include Openspace Ventures, Heliconia Capital, SGInnovate.